Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

Robert A Parker; Dustin J Rabideau; Paul E Sax; Camlin Tierney; Eric S Daar; Ann C Collier; Elena Losina; Kenneth A Freedberg

doi:10.1093/cid/cix176

Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study

Clin Infect Dis. 2017 Jun 1;64(11):1612-1614. doi: 10.1093/cid/cix176.

Authors

Robert A Parker^{1

2

3

4}, Dustin J Rabideau¹, Paul E Sax^{3

5}, Camlin Tierney⁶, Eric S Daar^{7

8}, Ann C Collier⁹, Elena Losina^{2

3

4

10

11

12}, Kenneth A Freedberg^{2

3

4

11

13

14}

Affiliations

¹ Biostatistics Center, and.
² Medical Practice Evaluation Center, Massachusetts General Hospital.
³ Harvard Medical School.
⁴ Harvard University Center for AIDS Research.
⁵ Division of Infectious Diseases, Brigham and Women's Hospital, and.
⁶ Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
⁷ Division of HIV Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, and.
⁸ David Geffen School of Medicine at UCLA, Los Angeles, California.
⁹ Division of Allergy and Infectious Diseases, University of Washington, Seattle; and.
¹⁰ Department of Orthopedic Surgery, Brigham and Women's Hospital.
¹¹ Department of Epidemiology, Boston University School of Public Health.
¹² Department of Biostatistics, Boston University School of Public Health.
¹³ Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, and.
¹⁴ Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts.

Abstract

In AIDS Clinical Trials Group A5202, participants who reported missing their medication within the past month or not providing adherence reports at both 8 and 24 weeks had 5 times the hazard of virological failure compared to more adherent participants. Adherence interventions should focus on such patients.

Keywords: HIV; adherence; missing medication; self-report; virologic failure..

Publication types

Clinical Trial, Phase III
Randomized Controlled Trial

MeSH terms

Adult
Anti-HIV Agents / administration & dosage*
Anti-HIV Agents / therapeutic use
Dideoxynucleosides / administration & dosage
Dideoxynucleosides / therapeutic use
Drug Combinations
Female
HIV Infections / drug therapy*
HIV-1 / drug effects
Humans
Lamivudine / administration & dosage
Lamivudine / therapeutic use
Male
Medication Adherence*
RNA, Viral / blood
Self Report
Tenofovir / administration & dosage
Tenofovir / therapeutic use
Treatment Failure
Viral Load / drug effects

Substances

Anti-HIV Agents
Dideoxynucleosides
Drug Combinations
RNA, Viral
abacavir, lamivudine drug combination
Lamivudine
Tenofovir

Abstract

Publication types

MeSH terms

Substances

Grants and funding